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adelaide.edu.auAbstractCirculating IGFs are important regulators of prenatal and postnatal growth, and of
metabolism and pregnancy, and change with sex, age and pregnancy. Single-nucleotide
polymorphisms (SNPs) in genes coding for these hormones associate with circulating
abundance of IGF1 and IGF2 in non-pregnant adults and children, but whether this occurs in
pregnancy is unknown. We therefore investigated associations of plasma IGF1 and IGF2 with
age and genotype at candidate SNPs previously associated with circulating IGF1, IGF2 or
methylation of the INS–IGF2–H19 locus in men (nZ134), non-pregnant women (nZ74) and
women at 15 weeks of gestation (nZ98). Plasma IGF1 concentrations decreased with age
(P!0.001) and plasma IGF1 and IGF2 concentrations were lower in pregnant women than in
non-pregnant women or men (each P!0.001). SNP genotypes in the INS–IGF2–H19 locus
were associated with plasma IGF1 (IGF2 rs680, IGF2 rs1004446 and IGF2 rs3741204) and IGF2
(IGF2 rs1004446, IGF2 rs3741204 and H19 rs217727). In single SNP models, effects of IGF2
rs680 were similar between groups, with higher plasma IGF1 concentrations in individuals
with the GG genotype when compared with GA (PZ0.016), or combined GA and AA
genotypes (PZ0.003). SNPs in the IGF2 gene associated with IGF1 or IGF2 were in linkage
disequilibrium, hence these associations could reflect other genotype variations within this
region or be due to changes in INS–IGF2–H19methylation previously associated with some of
these variants. As IGF1 in early pregnancy promotes placental differentiation and function,
lower IGF1 concentrations in pregnant women carrying IGF2 rs680 A alleles may affect
placental development and/or risk of pregnancy complications.Key Words
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omEndocrine Connections
(2014) 3, 138–149IntroductionThe insulin-like growth factors (IGFs), IGF1 and IGF2,
are important regulators of placental and foetal develop-
ment, as well as postnatal growth and metabolism. In
humans, circulating IGF1 peaks in adolescence and then
falls with age, whereas IGF2 concentrations remain fairly
stable after puberty (1). The pubertal peak in plasma
IGF1 occurs 1–2 years earlier in girls than in boys,resulting in higher circulating IGF1 concentrations in
girls than in boys through adolescence (2, 3). Plasma
IGF1 concentrations are fairly similar in men and
women (2, 4) but slightly lower circulating IGF1
concentration in adult women than in men has been
reported in large studies (3, 5). Plasma IGF2 is similar in
adolescent and young adult men and women (6, 7), butsed under a Creative Commons
nported License.
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2–12 3 :139whether IGF2 remains similar between sexes throughout
ageing is unknown.
IGF abundance is also altered by pregnancy. Variable
changes in circulating IGF1 during the first two trimesters
of human pregnancy have been reported, with modest
increases of 25–40% compared with non-pregnant women
(8) or a gradual overall rise with increasing gestation and
highly variable concentrations between women in cross-
sectional studies (9, 10). Longitudinal studies have shown
stable concentrations from early pregnancy (8–10 weeks)
until after 30 weeks of gestation (11, 12), or decreased
concentrations in the first trimester up until 24 weeks
of gestation compared with pre-conception (13, 14, 15).
All these studies agree that maternal circulating IGF1 is
45–200% higher in the third trimester when compared
with non-pregnant women, early pregnancy or pre-
conception (8, 9, 10, 11, 12, 13, 14, 15, 16). Fewer studies
have characterised circulating IGF2 abundance through-
out pregnancy. Gargosky et al. (8) reported much higher
plasma IGF2 concentrations than IGF1 concentrations in
pooled plasma from pregnant women, measured by RIA
after HPLC separation of samples to completely remove
IGF-binding proteins. IGF2 concentrations were highly
variable between different stages of pregnancy, but as these
were analysed in pooled samples it is difficult to draw
conclusions about changes across pregnancy (8). In an
early cross-sectional study, plasma IGF2 concentrations
were higher in women in the third trimester when
compared with the first trimester of pregnancy and
decreased post partum (10). Two longitudinal studies each
measuring IGF2 by RIA after acid–ethanol extraction
reported decreases of w10% in plasma IGF2 in the first
trimester compared with concentrations in the same
women before pregnancy (14, 15). As pregnancy pro-
gressed, plasma IGF2 returned to pre-conception concen-
trations (14) or increased to w10% above pre-conception
concentrations (15). In addition to effects on maternal
metabolism, IGFs act as endocrine signals to enhance
placental function and foetal growth (reviewed by (17)).
We have previously directly demonstrated the endocrine
actions of maternal IGFs to enhance placental differen-
tiation and function and hence foetal growth in the guinea
pig (18, 19, 20). Consistent with this, late pregnancy
maternal circulating IGF1 concentration is reduced in
human pregnancies complicated by IUGR compared with
those with normally grown neonates (11, 21).
Genetic variation also impacts the IGF axis and
circulating IGF1 and IGF2 differ between individuals
according to their genotype at single-nucleotide poly-
morphisms (SNPs) in the genes for IGF1, IGF2 and the IGF1http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0068
 2014 The authors
Published by Bioscientifica Ltdreceptor (IGF1R). Within the IGF1 locus, rs12579108 is
weakly associated with plasma IGF1 in children in
combination with other SNPs (22), while the rare C allele
of the IGF1 rs7965399 SNP was associated with increased
plasma IGF1 concentrations in older women but not
with plasma IGF1 concentrations in other populations
(23, 24, 25). Consistent with a positive effect of the IGF1
rs7965399 C allele on IGF1, this allele was also associated
with a trend towards higher IGF1 concentration in breast
tumours (26). Circulating IGF1 is also associated with
genotype at the IGF1R rs2229765 SNP, which is predicted
to regulate alternative splicing of IGF1R (27). The AA
genotype at this SNP predicts lower plasma IGF1 con-
centrations in adult men and women compared with
GG individuals in most (28, 29, 30), but not all, studies
(31, 32), with lower plasma IGF1 concentrations also
reported in AG heterozygotes (28). The AA genotype also
predicts increased longevity (28, 29, 30), and shorter male
adult height (33), consistent with decreased IGF1 action in
these individuals, as absence of IGF1 signalling through
IGF1R reduces postnatal growth (34), and IGF1 deficiency
predicts longevity (35).
IGF2 is located in an imprinted gene cluster on
chromosome 11p15.5 (Fig. 1), containing genes for H19,
IGF2, insulin (INS), tyrosine hydroxylase (TH) and an
antisense IGF2 gene overlapping with IGF2 (IGF2-AS). The
H19 long non-coding RNA in this cluster is maternally
expressed and this imprinting appears to remain stable
with age (36, 37). IGF2 and H19 are reciprocally imprinted
during early development and, in foetal, placental and
many adult tissues, IGF2 is paternally expressed from the
P0, P2, P3 and P4 promoters (36, 37, 38). P1 promoter
transcripts of IGF2 are expressed from both parental alleles
and IGF2 is expressed bi-allelically in liver from older
infants and adults, where imprinting of IGF2 is not closely
co-regulated with that of H19 (36, 37). We have recently
reported discordant imprinting of IGF2 and H19 in first
trimester human placenta at 6 weeks of gestation, where
expression of IGF2 is mono-allelic but imprinting of
H19 is highly variable (39). Individuals with Beckwith–
Wiedemann syndrome and loss of imprinting at this locus,
who therefore express maternal and paternal IGF2 alleles,
often have pre- and postnatal overgrowth, suggesting
increased IGF2 availability (reviewed by (40)). This
suggests that SNPs associated with altered DNA methyl-
ation at this locus may also regulate circulating IGF2.
Indeed, plasma IGF2 concentrations have previously been
associated with genotype at two SNPs associated with
INS–IGF2–H19 methylation. Specifically, IGF2 rs680 and
H19 rs217727 SNPs strongly correlate with methylation ofThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 1
Schematic of the Homo sapiens INS–IGF2–H19 locus. Exons are represented
as blue boxes with intronic regions between exons as black lines. Black
arrows above exons show transcription start sites and direction of
transcription. Orange boxes indicate the approximate location of
differentially methylated regions (DMRs). The x-axis shows genomic
position in base pairs for human chromosome 11 and the position of single-
nucleotide polymorphisms (SNPs, denoted by rs number) investigated in
this study. This representation is based on human reference genome hg19,
dbSNP 138 and RefSeq transcripts.
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3–12 3 :140multiple CpG sites within the IGF2 and H19 differentially
methylated regions respectively (41). Circulating IGF2
concentrations were higher in individuals homozygous
for the A allele at IGF2 rs680 (ApaI), compared with those
homozygous for the G allele in middle-aged men (42).
The A allele is also part of a haplotype of four SNPs that
are positively associated with IGF2 protein content of
placentas collected at term (43). Others found no effect
of IGF2 rs680 on plasma IGF2 concentrations in studies
of middle-aged to elderly men and women (44, 45, 46).
Conversely, the IGF2 rs680 G allele was associated with
higher IGF2 mRNA expression in leukocytes (47).
Neonatal IGF2 rs680 A alleles were associated with lower
birth weight than G alleles in Brazilian and Japanese
populations (48, 49). By contrast, maternal (50) or
neonatal (43, 50, 51) IGF2 rs680 genotypes were not
associated with birth weight in Caucasian populations.
A paternally inherited foetal A allele at IGF2 rs680 was,
however, associated with higher maternal circulating
glucose post-challenge at 27–29 weeks of gestation (43),
consistent with an effect of this allele on maternal
adaptation to pregnancy. Only one study has investigated
differences in circulating IGF2 with the H19 rs217727 SNP.
The presence of one or more T alleles at H19 rs217727
in women was positively associated with birth size and
cord blood IGF2 in their neonates, with the TT genotype
relatively rare (!5%) in mothers and newborns (52).
Methylation of the INS–IGF2–H19 locus also differs
according to genotype at IGF2 rs1004446 (41) and IGF2
rs3741204. IGF2 rs3741204 is located within the P3
promoter of IGF2 within the DMR0 region that affects
imprinting of IGF2 and H19. The A allele is observed in
two different four SNP haplotypes associated with eitherhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0068
 2014 The authors
Published by Bioscientifica Ltdincreased or decreased methylation of the INS–IGF2–H19
locus in Beckwith–Wiedemann syndrome (53). Associ-
ations of IGF2 rs1004446 and IGF2 rs3741204 with
circulating IGF2 have not been reported as yet.
Although relationships between SNP genotype and
circulating IGFs have been previously investigated in
non-pregnant subjects, no studies to date have reported
their associations in pregnant women, when circulating
IGF concentrations regulate placental and foetal growth
and development (17). We therefore investigated
whether relationships between circulating IGF1 and
IGF2 abundance and SNP genotypes previously associ-
ated with circulating IGFs (IGF1 rs12579108, IGF1
rs7965399, IGF1R rs2229765, IGF2 rs680 and H19
rs217727) and/or methylation of the INS–IGF2–H19
locus (IGF2 rs680, IGF2 rs1004446, IGF2 rs3741204 and
H19 rs217727) differ among men, pregnant women and
non-pregnant women.Materials and methods
Study populations and sample collection
Circulating IGFs and genotype data from Caucasian
subjects within two independent studies are included
in the present analysis. Non-pregnant women were from
a general population cohort and pregnant women from
a subset of the Adelaide Screening for Pregnancy End-
points (SCOPE) cohort, who had a normal pregnancy
outcome, as described below, while male subjects were
from the general population or partners of the pregnant
women (Table 1).This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Table 1 Subject characteristics. This study includes only Caucasian individuals with data for circulating IGFs and
genotype. Subject characteristics are expressed as median (range).
Men Non-pregnant women Pregnant women
Number 134 74 98
Age (years) 25.0 (17–59) 23.5 (18–51) 23.0 (14–39)
Body weight (kg) 82.0 (55.0–133.1) 64.0 (43.0–100.0) 72.5 (44.8–125.1)
Height (m) 1.81 (1.64–1.96) 1.66 (1.53–1.78) 1.65 (1.49–1.82)
BMI (kg/m2) 24.7 (18.0–37.0) 23.1 (17.7–39.5) 26.8 (17.7–44.8)
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4–12 3 :141Healthy, non-pregnant adults were recruited from the
general population in Adelaide, South Australia, and gave
informed consent for participation in the study. Inclusion
criteria were age (18–60 years) and not taking regular
medication other than the oral contraceptive pill. First-
degree (siblings, parent–child) and second-degree relatives
(cousins) were excluded. Ethics approval for this work
was given by the University of Adelaide Human Research
Ethics Committee (H-021-2005).
Pregnant women and their partners were recruited
from a nested case–control study within the Adelaide
SCOPE cohort, an international prospective cohort
study recruiting patients in Australia, New Zealand
(ACTRN12607000551493, Australian and New Zealand
Clinical Trials Registry), UK and Ireland, which aims to
predict and prevent the major complications of late
pregnancy (54). Women who were nulliparous with a
singleton pregnancy at!15 weeks of completed gestation
and with no more than two previous terminations of
pregnancy or miscarriages were recruited into the
Adelaide cohort after providing written informed consent
at the Lyell McEwin Hospital antenatal clinic (Elizabeth
Vale, SA, Australia). This study includes only women
who had an uncomplicated pregnancy, defined as
women who remained normotensive (!140 mmHg sys-
tolic and/or!90 mmHg diastolic prior to labour), showed
no proteinuria, delivered a live born baby who was not
small for gestational age after 37 weeks of completed
gestation and had no other signs of pregnancy compli-
cations. The pregnant women in this study were the 98
women in whom genotype and circulating IGF data were
available, from a cohort of 133 control women with normal
pregnancy outcomes, BMI-matched to pregnant women
who later developed preeclampsia or gestational
hypertension (55) or gestational diabetes or who delivered
before 37 weeks of completed gestation (preterm) or a
small-for-gestational-age infant. Ethics approval for this
work was given by the Ethics of Human Research
Committee, Central Northern Adelaide Health Service
(REC 1712/5/2008).http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0068
 2014 The authors
Published by Bioscientifica LtdNon-fasting blood samples were collected by vene-
puncture from women at 15 weeks of gestation, and their
partners sometimes, during the women’s pregnancy, and
from general population subjects. Samples were collected
into EDTA tubes and placed on ice, before centrifugation
at 2400 g for 10 min at 4 8C. Plasma and buffy coats were
harvested and stored at K80 8C for subsequent analyses.Plasma IGF1 and IGF2 analyses
Concentrations of plasma IGF1 and IGF2 were measured by
RIA after separation of IGFs and IGFBPs by size-exclusion
HPLC under acidic conditions (8, 56). Four fractions of
eluate (fraction 1, containing IGFBPs; fraction 2, inter-peak;
fraction 3, containing IGFs and fraction 4, post-peak) were
routinely collected for each acidified plasma sample, using
collection times based on elution times of 125I-IGF1 and IGF
immunoreactivity. Recovery of 125I-IGF1 was 88.0G1.1%
for five HPLC runs of human plasma. Samples were assayed
in triplicate. Plasma IGF1 concentrations were measured by
analysis of neutralised HPLC fraction 3, in an RIA specific for
IGF1, using a rabbit polyclonal antibody to human IGF1
(GroPep, Adelaide, SA, Australia). Plasma IGF2 concen-
trations were measured by analysis of HPLC fraction 3 in an
RIA specific for IGF2 (57), using a mouse MAB against rat
IGF2,whichhas100%cross-reactivitywithhumanIGF2and
!10% cross-reactivity with human IGF1 (anti-IGF2 clone,
Millipore, St Charles, MO, USA). Inter- and intra-assay
coefficient of variation (CV) values for HPLC separation and
IGF1 RIA of a non-pregnant female QC human plasma pool
were !19 and !14% respectively (14 assays). Inter- and
intra-assay CV values for HPLC separation and IGF2 assays
were!15 and!10% respectively (13 assays).DNA extraction and genotyping
A series of SNPs previously shown to affect circulating
abundance of IGF1 (IGF1 rs1257918, IGF1 rs7965399 and
IGF1R rs2229765), circulating abundance of IGF2 (IGF2
rs680 and H19 rs217727), and/or methylation of theThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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5–12 3 :142INS–IGF2–H19 locus (IGF2 rs680, IGF2 rs3741204, IGF2-AS
rs1004446 and H19 rs217727) were genotyped in extracted
DNA. DNA was extracted from buffy coats using the
X-Tractor Gene (Corbett Robotics Pty Ltd, Eight Mile
Plains, QLD, Australia) following the manufacturer’s
instructions or by the Australian Genome Research Facility
(AGRF, Adelaide, SA, Australia) using the Machery Nagel
Nucleospin 96-well format. Genotyping was performed at
AGRF (Brisbane, OLD, Australia) using the Sequenom
MassARRAY System. The assay used the iPLEX Gold
homogenous MassExtend (hME – single base extension)
reaction. Oligonucleotides obtained were used to process
samples in the multiplex format, then printed onto Spectro
CHIPs and analysed by MALDI–TOF mass spectrometry. All
genotypes were in Hardy–Weinberg equilibrium and the
genotype pass rate wasO96% across all SNPs.
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m
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200
0
10 20 30 40 50 60 70
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Figure 2
Circulating plasma IGF1 and IGF2 in men (white squares), non-pregnant
women (grey circles) and at 15 weeks of gestation in pregnant women
(black circles).Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics
v 21. Circulating IGF concentrations were log transformed
before analyses to overcome unequal variances. Effects of
group (male, non-pregnant female or pregnant female) on
circulating IGF concentrations were analysed by ANOVA,
including age as a covariate, and groups compared using the
Bonferroni’s correction for multiple comparisons. In initial
analyses, BMI did not alter circulating IGF concentrations
when included as a covariate in univariate analyses for effects
ofgroup orwhen included in preliminary regression analyses
(data not shown) and BMI was therefore not included as
a covariate in final analyses. Effects of group on SNP
frequencies were assessed by the c2 analysis, or by Fisher’s
exact test for rare alleles. Predictors of plasma IGF concen-
trations were derived by stepwise backward linear regression
commencing from a model including group, age, and
common allele frequency for each SNP. Age was included
as a covariate in models with circulating IGF1 as an outcome.
For each SNP identified as significant or approaching
significance (P!0.1) in stepwise linear regressions, we tested
the effects of SNP genotype, group and interactions on
circulating IGF concentrations in two-way ANOVA
and performed pair-wise cross-tabulation to determine
whether these SNPs were in linkage disequilibrium.Results
Circulating IGF1 and IGF2
Plasma IGF1 concentrations (Fig. 2A) decreased with age
(P!0.001) and differed between groups (P!0.001). Plasmahttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0068
 2014 The authors
Published by Bioscientifica LtdIGF1 concentrations in women at 15 weeks of gestation
were 31 and 45% lower than those in men or non-pregnant
women respectively (P!0.001 for both). Plasma IGF2
concentrations (Fig. 2B) tended to decrease with age
(PZ0.078) and differed between groups (P!0.001). Plasma
IGF2 concentrations in women at 15 weeks of gestation
were 9 and 12% lower than those in men or non-pregnant
women respectively (P!0.001 for both). Neither plasma
IGF1 nor IGF2 concentrations differed between men and
non-pregnant women. Effects of age on plasma IGF1 and
IGF2 concentrations were similar between groups.SNP genotype frequencies
Frequencies of individuals homozygous for the rare allele
of the seven SNPs investigated varied from 18% for IGF1R
rs2229765 to 0% for IGF1 rs12579108 and IGF1 rs7965399
(Table 2). Genotype frequencies did not differ among men,
non-pregnant women and pregnant women (Table 2).This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Table 2 SNP genotype frequencies.
SNP and population Genotype, n (%) Significance*
IGF1 rs12579108 CC CA AA 0.383
Men 130 (98) 2 (2) 0 (0)
Non-pregnant women 73 (99) 1 (1) 0 (0)
Pregnant women 93 (96) 4 (4) 0 (0)
Total 296 (98) 7 (2) 0 (0)
IGF1 rs7965399 TT TC CC 0.591
Men 124 (95) 6 (5) 0 (0)
Non-pregnant women 68 (92) 6 (8) 0 (0)
Pregnant women 86 (93) 6 (7) 0 (0)
Total 278 (94) 18 (6) 0 (0)
IGF2 rs680 GG GA AA 0.101
Men 71 (56) 48 (38) 8 (6)
Non-pregnant women 39 (59) 20 (30) 7 (11)
Pregnant women 50 (52) 44 (46) 2 (2)
Total 160 (55) 112 (39) 17 (6)
IGF2 rs3741204 AA AG GG 0.273
Men 54 (43) 60 (47) 13 (10)
Non-pregnant women 17 (29) 34 (58) 8 (14)
Pregnant women 34 (37) 43 (46) 16 (17)
Total 105 (38) 137 (49) 37 (14)
IGF2 rs1004446 CC CT TT 0.698
Men 58 (45) 58 (45) 14 (11)
Non-pregnant women 30 (42) 32 (45) 9 (13)
Pregnant women 36 (37) 45 (46) 16 (16)
Total 124 (42) 135 (45) 39 (13)
H19 rs217727 CC CT TT 0.756
Men 83 (63) 45 (34) 3 (2)
Non-pregnant women 45 (62) 24 (33) 4 (5)
Pregnant women 62 (65) 29 (31) 4 (4)
Total 190 (64) 98 (33) 11 (4)
IGF1R rs2229765 GG GA AA 0.222
Men 44 (34) 65 (50) 22 (17)
Non-pregnant women 25 (35) 31 (43) 16 (22)
Pregnant women 22 (24) 56 (60) 15 (16)
Total 91 (31) 152 (51) 53 (18)
*P values for differences in genotype frequencies between groups were derived using the c2 test, except for rare alleles (IGF1
rs12579108 and H19 rs217727), where frequencies were compared using Fisher’s exact test.
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6–12 3 :143Effects of SNP genotype on circulating IGF1
concentrations
In overall regression models including data from all
subjects, plasma IGF1 differed between groups
(P!0.001), decreased with age and differed with a
common allele frequency of three SNPs in the INS–IGF2–
H19 gene locus (Table 3). Overall, plasma IGF1 correlated
positively with the numbers of the common G allele of
IGF2 rs680 and the common C allele of IGF2 rs1004446,
and correlated negatively with the numbers of the
common A allele of IGF2 rs3741204. Similar correlations
of plasma IGF1 with age and SNP frequencies were
observed in non-pregnant women (Table 3). Within men
alone, plasma IGF1 correlated negatively with age and washttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0068
 2014 The authors
Published by Bioscientifica Ltdnot correlated with the allele number for any SNP
(Table 2). In pregnant women, plasma IGF1 correlated
negatively with age and positively with the number of the
common G allele of IGF2 rs680 (Table 3).
In separate analyses of associations of each SNP (IGF2
rs680, IGF2 rs1004446 and IGF2 rs3741204), plasma IGF1
differed between groups (P%0.002 for each model) and
correlated negatively with subject age (P!0.001 for each
model). Plasma IGF1 concentration differed between IGF2
rs680 genotypes, being higher in GG individuals
compared with GA individuals alone (PZ0.016) or with
GA and AA genotypes combined (PZ0.003, Fig. 3). Effects
of IGF2 rs680 genotype on plasma IGF1 concentration did
not differ between groups. Plasma IGF1 did not differ
between IGF2 rs1004446 and IGF2 rs3741204 genotypes.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Table 3 Predictors of plasma IGF concentrations overall, in men, non-pregnant women and pregnant
women. SNP names are shown in the form of gene names, SNP number (alleles). Correlations are partial
correlations for each factor in the final model and total correlation for the model. The most common allele is
shown first and the ancestral allele is underlined. Predictors of plasma hormone concentrations were derived
using the natural log of plasma concentrations as outcomes by stepwise backward linear regression
commencing with a model including subject group (for overall model only), age and common allele
frequency for each SNP.
Groups Predictors r P value
Plasma IGF1
Overall Group K0.390 !0.001
Age K0.350 !0.001
IGF2 rs680 (GOA) 0.190 0.002
IGF2 rs3741204 (AOG) K0.206 0.001
IGF2 rs1004446 (COT) 0.200 0.001
Model 0.501 !0.001
Men Age K0.439 !0.001
Model 0.439 !0.001
Non-pregnant women Age K0.405 0.004
IGF2 rs680 (GOA) 0.257 0.074
IGF2 rs3741204 (AOG) K0.281 0.050
IGF2 rs1004446 (COT) 0.246 0.089
Model 0.535 0.003
Pregnant women Age K0.197 0.068
IGF2 rs680 (GOA) 0.206 0.055
Model 0.289 0.025
Plasma IGF2
Overall Group K0.194 0.002
IGF2 rs3741204 (AOG) K0.158 0.010
H19 rs217727 (COT) K0.103 0.096
IGF2 rs1004446 (COT) 0.153 0.014
Model 0.257 0.001
Men No significant predictors
Non-pregnant women No significant predictors
Pregnant women No significant predictors
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7–12 3 :144Effects of SNP genotype on circulating
IGF2 concentrations
Overall, plasma IGF2 concentrations differed between
groups (PZ0.002) and with common allele numbers of
three SNPs in the INS–IGF2–H19 gene locus (Table 3), but
were not affected by age. Plasma IGF2 correlated positively
with the number of the common C allele of IGF2
rs1004446 and negatively with the numbers of the
common A allele of IGF2 rs3741204 and the common
C allele of H19 rs217727 (Table 3). Within men alone,
non-pregnant women alone, or pregnant women alone,
plasma IGF2 was not correlated with allele frequencies
for any SNP (Table 3).
In separate analyses of associations of each SNP with
plasma IGF2, plasma IGF2 differed between groups
(P%0.002 for each model), but did not differ among
IGF2 rs3741204, IGF2 rs1004446 or IGF2 rs3741204
genotypes.http://www.endocrineconnections.org
DOI: 10.1530/EC-14-0068
 2014 The authors
Published by Bioscientifica LtdLinkage analysis
The three SNPs identified in stepwise backward
regression as predictive of circulating IGF1 were in
linkage disequilibrium, particularly strong between
IGF2 rs3721204 and IGF2 rs1004446. Within the overall
population, 97.8% of individuals (P!0.001) with AA,
AG and GG genotypes at IGF2 rs3721204 had CC, CT
and TT genotypes, respectively, at IGF2 rs1004446,
located 235 nucleotides distant within the IGF2 gene
(Fig. 1). Genotype of IGF2 rs680 shared 34.4% con-
cordance with IGF2 rs1004446 (PZ0.007) and 32.0%
concordance with IGF2 rs3721204 (PZ0.016). Two of the
three SNPs identified in stepwise backward regression as
predictive of circulating IGF2 were in linkage disequili-
brium, IGF2 rs3721204 and IGF2 rs1004446, as described
above. Genotype at H19 rs217727 tended towards
concordance with IGF2 rs1004446 genotype (PZ0.053)
but not with IGF2 rs3721204 genotype.This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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This study provides the first comparison of circulating IGF
abundance in men, non-pregnant and pregnant women
within the same population. Similar plasma IGF1 concen-
trations in non-pregnant women and men and falling
plasma IGF1 concentrations with age were consistent with
previous information, while a lack of change in plasma IGF2
in these mature adults with sex or age extends previous
findings of similar plasma IGF2 abundance in male and
female children and adolescent humans. IGF1 and IGF2
concentrations in circulation were both lower in pregnant
women at 15 weeks of gestation than in either men or non-
pregnant women. For the first time, we identified differences
in circulating IGF1 between individuals according to
common allele numbers in three linked SNPs in the INS–
IGF2–H19 locus. Associations between circulating IGF1 and
IGF2 rs680 genotype remained significant in single SNP
models and were consistent among men, non-pregnant
women and pregnant women. This suggests that effects of
SNP genotype in the INS–IGF2–H19 locus are consistent
between sexes and unaffected by pregnancy.Overall, plasma
IGF2 concentrations were also predicted by common allele
numbersof three SNPs in the INS–IGF2–H19 locus, including
two SNPs for which the common allele number also
correlated with plasma IGF1. Our results show genotypes
in the IGF2 region of the INS–IGF2–H19 locus associated
with circulating IGF1 and IGF2 concentrations, which
requires confirmation in additional independenthttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0068
 2014 The authors
Published by Bioscientifica Ltdpopulations. This is the first report of lower circulating
IGF1 concentration in pregnant women with the A allele at
IGF2 rs680 SNP genotype. Given the endocrine actions of
maternal IGFs in pregnancy, we hypothesise that IGF2 rs680
genotype may affect placental development and function
and maternal adaptation to pregnancy. We are currently
exploring these effects in women who experienced preg-
nancy complications in a separate study.
Circulating IGF1 concentrations were lower in women
at 15 weeks of gestation than in either men or non-
pregnant women in this study. Our data, obtained using a
methodology that completely separates IGFs from IGFBPs
before assay and prevents IGFBP interference in IGF assays,
are consistent with previous reports of reductions in
circulating IGF1 during early–mid pregnancy from longi-
tudinal studies (14, 15). We hypothesise that this decrease
of w45% in circulating IGF1 at 15 weeks of gestation,
compared with non-pregnant women, largely reflects
increased negative feedback on IGF1 production, due to
increased IGF1 bioavailability despite reduced total IGF1
concentrations. Proteolysis of IGFBP3 and other IGFBPs
increases rapidly in human pregnancy by w6–8 weeks of
gestation and decreases their binding affinity for IGFs,
which increases circulating concentrations of free or
unbound IGFs available to bind receptors (58, 59, 60).
The placenta produces two metalloproteinases which
proteolyse IGFBPs: pregnancy-associated plasma protein
A (PAPPA), which cleaves IGFBP4 and to a lesser extentThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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9–12 3 :146IGFBP5 (reviewed by (61)), and PAPPA2, which mostly
cleaves IGFBP5 (62). Haemodilution, due to expansion of
maternal blood volume in early pregnancy, may also
account for w20–25% of the fall in circulating IGF1
concentration that we observed (14).
The increases in circulating IGF1 concentration
reported in later pregnancy (8, 9, 11, 14, 16) are probably a
response to increasing maternal circulating GH concen-
trations stimulated by rapid increases in placental GH
production during the second trimester (63). These result
in elevated, non-pulsatile GH concentration in maternal
circulation from 17–24 weeks of gestation (63, 64). Plasma
IGF1 and IGF2 normalise across gestation inwomen who are
deficient in pituitary GH (65), implying that placental GH is
a major regulator of IGF abundance during pregnancy.
Furthermore, the human placenta itself expresses IGF1 and
IGF2, and IGF1 gene and protein expression occurs on both
maternal and foetal sides of the human placenta (66, 67),
and placental tissues might therefore be a source of
circulating IGFs during pregnancy. This study is the first to
show that IGF1 falls with age in pregnant women, while
the decrease with age in non-pregnant women is consistent
with previous reports that IGF1 falls from young to old
adulthood (4). Plasma IGF1 did not differ between non-
pregnant women and men, consistent with most previous
studies, where although the pattern of change in circulating
IGF1 throughout puberty differed between sexes, plasma
concentrations are similar in men and women as young and
old adults (2, 4). Small sex differences were evident in a
recent multi-centre study with over 15 000 subjects, where
circulating IGF1 concentrations were slightly lower in
women than men (5).
The 12% lower IGF2 concentration in pregnant
women at 15 weeks of gestation compared with non-
pregnant women at similar ages is consistent with the
magnitude of reductions in circulating IGF2 at similar
stages of pregnancy reported previously in longitudinal
studies (14, 15). This early-pregnancy fall in IGF2 was
explained by haemodilution (14) due to expansion of
maternal blood volume in early pregnancy. Our findings
across the adult age range in this study extend those from
studies in children throughout puberty and up to young
adulthood (6, 7), where plasma IGF2 concentrations also
do not change with age or differ between sexes.
Our results provide the first evidence that SNP
genotypes in the INS–IGF2–H19 locus associate with
circulating concentrations of IGF1, as well as IGF2. The
number of IGF2 rs680 common G alleles was positively
associated with circulating IGF1 concentrations overall
and in non-pregnant and pregnant women analysedhttp://www.endocrineconnections.org
DOI: 10.1530/EC-14-0068
 2014 The authors
Published by Bioscientifica Ltdseparately. Associations of genotypes at this SNP with
circulating IGF1 were robust and did not differ among
men, non-pregnant or pregnant women in univariate
analysis. In this study, individuals with the IGF2 rs680 GA
or GACAA genotypes consistently had lower plasma IGF1
concentrations than those homozygous for the G allele.
The G allele has previously been associated with lower
circulating IGF2 concentrations than the A allele in
middle-aged men (42), but we did not find any association
between genotype at this SNP and plasma IGF2 in this
study. This suggests that associations between IGF2 rs680
and circulating IGF1 do not reflect competition with
circulating IGF2 for IGFBP-binding sites and consequent
effects on circulating half-life. IGF2 is imprinted and only
the paternally inherited allele is expressed in many, but
not all, tissues postnatally (37). Differences in circulating
IGF1 between GG and GACAA genotypes observed in this
study are therefore likely to be smaller than the actual
effects of the paternally expressed alleles of IGF2 rs680, as
the GA heterozygotes will include individuals with
paternally inherited A and G alleles. As these three SNPs
in IGF2 were in linkage disequilibrium within this
population, associations of circulating IGF1 with IGF2
rs680 SNP genotype could reflect variation anywhere
within this region. Nevertheless, they do suggest that
genotypes at this locus might affect placental develop-
ment and maternal adaptation to pregnancy via effects on
IGF1 or IGF2 abundance, given that both these peptides
are endocrine regulators of placental growth and differen-
tiation (17). Further studies are needed to confirm these
effects of INS–IGF2–H19 locus SNP genotypes on circulat-
ing IGF1, to investigate underlying mechanisms and assess
potential effects on the placenta and mother.
Across all groups combined (nZ307), SNP genotype at
IGF2 rs3741204, H19 rs217727 and IGF2 rs1004446
correlated with circulating plasma IGF2 in multiple linear
regression analyses. A negative association of the common
C allele of H19 rs217727 with circulating IGF2 concen-
trations is consistent with the reported effects of this SNP
on cord blood IGF2 (52). This study provides the first
evidence that SNP genotype at IGF2 rs3741204 or IGF2
rs1004446 may affect circulating IGF2. Genotypes at these
two SNPs were extremely tightly linked in this population,
consistent with their proximity within the IGF2 and
IGF2-AS genes at 235 nucleotides apart. These associations
might therefore reflect effects of either of these SNPs or of
other SNPs in this linkage region. Our findings, together
with previously reported associations between IGF2 rs680
genotype and circulating IGF2 in one study of middle-
aged men (42), are also consistent with the hypothesis thatThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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10–12 3 :147SNPs that are associated with altered methylation of the
INS–IGF2–H19 locus, such as IGF2 rs3741204, IGF2
rs1004446 and IGF2 rs680 (41, 53), may affect IGF2
expression and secretion. Further investigations are
required to identify which SNP or SNPs in this region
alter(s) the methylation and expression of IGF2. The loss of
associations of any SNPs with circulating IGF2 in men
(nZ134), non-pregnant women (nZ74) or pregnant
women (nZ98) in regression models run separately in
each group, or when analysing effects of genotype and
group separately for each SNP, probably reflects the
limited power due to smaller sample sizes within each
sub-group of this study. Comparing effects of these three
SNPs between sexes and in pregnant and non-pregnant
populations will require additional, larger studies.
In conclusion, plasma IGF1 and IGF2 concentrations
were lower in pregnant women at 15 weeks of gestation
than in men or non-pregnant women and did not differ
between adult men and non-pregnant women. We have
identified SNPs in the INS–IGF2–H19 locus associated with
circulating IGF1, as well as IGF2. Associations between
IGF2 rs680 and circulating IGF1 did not differ among men,
non-pregnant and pregnant women. As maternal circulat-
ing IGFs in early–mid pregnancy are endocrine regulators
of placental development and function, these genotypes
may also predict foetal growth and risk for pregnancy
complications. Further studies are needed to confirm these
putative effects of SNPs in the INS–IGF2–H19 locus on
circulating IGF1 and IGF2 concentrations and identify the
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